Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
FOLD is in the medium-term down -11% below S&P in 6 months.
Description: Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company?s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha g
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-40.12%||ROE||-74.29%||ROI||-61.43%|
|Current Ratio||7.19||Quick Ratio||Long Term Debt/Equity||0.07||Debt Ratio||0.2|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||4.06 M||Cash From Investing Activities||21.66 M||Cash From Operating Activities||-20.98 M||Gross Profit|
|Net Profit||-24.29 M||Operating Profit||-24.06 M||Total Assets||192.62 M||Total Current Assets||151.25 M|
|Total Current Liabilities||21.02 M||Total Debt||14.4 M||Total Liabilities||88.61 M||Total Revenue|
|High 52 week||17.09||Low 52 week||8.38||Last close||12.25||Last change||-2.62%|
|RSI||35.01||Average true range||0.62||Beta||1.18||Volume||3.52 M|
|Simple moving average 20 days||-6.53%||Simple moving average 50 days||-8.64%||Simple moving average 200 days||0.24%|
|Performance Week||-3.77%||Performance Month||-4.82%||Performance Quart||7.27%||Performance Half||13.64%|
|Performance Year||-23.72%||Performance Year-to-date||27.87%||Volatility daily||2.42%||Volatility weekly||5.4%|
|Volatility monthly||11.07%||Volatility yearly||38.34%||Relative Volume||222.44%||Average Volume||3.04 M|
|New High||New Low|
2019-09-07 09:30:01 | Why Is Amicus Therapeutics FOLD Down 18.9% Since Last Earnings Report?
2019-09-04 07:00:00 | Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019
2019-08-19 09:35:16 | Is Amicus Therapeutics, Inc.'s NASDAQ:FOLD CEO Overpaid Relative To Its Peers?
2019-08-12 10:59:02 | Amicus FOLD Q2 Earnings Match, Stock Falls on Weak Q3 View
2019-08-10 01:30:55 | Amicus Therapeutics Inc FOLD Q2 2019 Earnings Call Transcript
2019-08-09 04:53:04 | Edited Transcript of FOLD earnings conference call or presentation 8-Aug-19 12:30pm GMT
2019-08-08 09:25:01 | Amicus Therapeutics FOLD Reports Q2 Loss, Tops Revenue Estimates
2019-07-29 07:00:00 | Amicus Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019
2019-07-22 13:07:00 | New Jersey biotech firm to open Lake Nona office, lab
2019-07-04 11:51:00 | Why Amicus Therapeutics' Stock Perked Up in June
2019-06-19 21:59:00 | Is Amicus Therapeutics, Inc. FOLD A Good Stock To Buy?
2019-06-12 17:49:39 | New Jersey biotech firm scales back Lake Nona plans
2019-06-12 08:44:00 | 2 Small Biotechs With Sagging Shares but Promising Prospects
2019-06-07 09:30:01 | Why Is Amicus Therapeutics FOLD Down 9.6% Since Last Earnings Report?
2019-06-04 16:01:00 | Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock
2019-06-03 07:00:00 | Amicus Therapeutics to Present at Upcoming Scientific and Investor Conferences
2019-05-30 21:00:00 | Amicus Therapeutics Prices Underwritten Offering of Common Stock
2019-05-30 16:29:00 | Why NIO, PVH, and Amicus Therapeutics Slumped Today
2019-05-30 14:11:00 | Here's Why Amicus Therapeutics Fell as Much as 15.6% Today
2019-05-30 10:34:00 | 2 Ultra-High-Growth Biotech Stocks to Buy Now
2019-05-29 16:14:50 | Amicus Therapeutics Announces Public Offering of Common Stock
2019-05-29 11:36:45 | Amicus, Penn expand gene therapy collaboration in a big way
2019-05-24 09:00:02 | Here Are Amicus’s Key Research Programs in 2019
2019-05-24 07:30:29 | How Is Amicus Therapeutics’ Galafold Placed in the First Quarter?
2019-05-23 11:10:02 | Comparing the EPS Trajectory of FOLD and PTLA in Fiscal 2019
2019-05-23 09:40:02 | FOLD and PTLA: What to Expect from Revenue Growth in Fiscal 2019
2019-05-23 08:08:46 | What Are Analysts Recommending for FOLD and PTLA in May?
2019-05-13 17:00:00 | Amicus Therapeutics Appoints Burke W. Whitman to its Board of Directors
2019-05-09 15:21:07 | Amicus' FOLD Earnings & Revenues Miss Estimates in Q1
2019-05-08 18:18:09 | Edited Transcript of FOLD earnings conference call or presentation 8-May-19 12:30pm GMT
2019-05-08 16:23:41 | Amicus Therapeutics Inc FOLD Q1 2019 Earnings Call Transcript
2019-05-08 08:25:12 | Amicus Therapeutics FOLD Reports Q1 Loss, Lags Revenue Estimates
2019-05-08 07:24:22 | Amicus Therapeutics: 1Q Earnings Snapshot
2019-05-08 07:00:00 | Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates
2019-05-03 09:51:01 | What's in Store for Catalyst Pharma CPRX Q1 Earnings?
2019-04-30 20:00:00 | 3 Growth Stocks to Buy and Hold for the Next 50 Years